Inhibition of cyclooxygenase-2 by NS-398 following hemorrhage/subsequent sepsis: No beneficial effects in either gender

Surgical Infections

Volumn 5, Issue 1, 2004, Pages 29-37

  Kahlke, Volker ^a   Seidel, Mirja ^a   Stapela, Sietje ^a   Broẗzmann, Kerstin ^a   Schafmayer, Clemens ^a   Schröder, Jörg ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PLACEBO; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CECUM; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; FLUID THERAPY; HEMORRHAGIC SHOCK; IMMUNE RESPONSE; IN VITRO STUDY; LIGATION; MACROPHAGE; MALE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PUNCTURE; SEPSIS; SEX DIFFERENCE; SPLEEN CELL; STATISTICAL SIGNIFICANCE; SURGICAL INFECTION; SURVIVAL;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; FEMALE; INJECTIONS, INTRAPERITONEAL; ISOENZYMES; MALE; MICE; MICE, INBRED CBA; NITROBENZENES; PROBABILITY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEPSIS; SEX FACTORS; SHOCK, HEMORRHAGIC; SULFONAMIDES; SURVIVAL ANALYSIS;

EID: 2942511689     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/109629604773860282     Document Type: Article

References (28)

1. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg 1992;216: 117-134.
2. Chaudry IH, Ayala A, Ertel W, Stephan RN. Hemorrhage and resuscitation: Immunological aspects. Am J Physiol 1990;259:R663-R678.
3. Baue AE, Durham, R, Faist E. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrom (MODS), multiple organ failure (MOF): Are we winning the battle? Shock 1998;10:79-89.
4. Ertel W, Morrison, MH, Wang P, et al. The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukin. Ann Surg 1991;214:141-148.
5. Ayala A, Lehman DL, Herdon CD, Chaudry IH. Mechanism of enhanced susceptibility to sepsis following hemorrhage. Arch Surg 1994;129:1172-1178.
6. Mack Strong VE, Mackrell PJ, Concannon EM, et al. NS-398 treatment after trauma modifies NF-kappa β activation and improves survival. J Surg Res 2001; 98:40-46.
7. Mackrell PJ, Daly JM, Mestre JR, et al. Elevated expression of cyclooxygenase-2 contributes to immune dysfunction in a murine model of trauma. Surgery 2001;130:826-833.
8. McGowan JE Jr, Barnes MW, Finland M. Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis 1975; 132:316-335.
9. Schröder J, Kahlke V, Staubach KH, et al. Gender differences in human sepsis. Arch Surg 1998;133:1200-1205.
10. Wichmann MW, Zellweger R, DeMaso CM, et al. Enhanced immune responses in females, as opposed to decreased responses in males following hemorrhagic shock and resuscitation. Cytokine 1996;8:853-863.
11. Kahlke V, Angele MK, Schwacha MG, et al. Reversal of sexual dimorphism in splenic T lymphocyte responses after trauma-hemorrhage with aging. Am J Physiol 2000;278:C509-C516.
12. Kahlke V, Dohm C, Brötzmann K, et al. Gender-related therapy: Early IL-10 administration following hemorrhage restores immune dysfunction in males but not in females. Shock 2000;14:354-360.
13. Kahlke V, Dohm C, Mees T, et al. Early IL-10 treatment improves survival and enhances immune function only in males after hemorrhagic shock and subsequent sepsis. Shock 2002;18:24-28.
14. Rugh R, Ed. The mouse: Its reproduction and development. Oxford: Oxford University Press, 1993:7-43.
15. Stephan RN, Kupper TS, Geha AS, et al. Hemorrhage without tissue trauma produces immunosuppression and enhances susceptibility to sepsis. Arch Surg 1987 122:62-68.
16. Futaki N, Takahashi S, Kitagawa et al. Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo. Inflamm Res 1997;46:496-502.
17. Baker CC, Chaudry IH, Gaines HO, Baue AE. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 1983;94:331-335.
18. Ayala A, Perrin MM, Wagner MA, Chaudry IH. Enhanced susceptibility to sepsis following simple hemorrhage: Depression of Fc and C3b receptor mediated phagocytosis. Arch Surg 1990;125:70-75.
19. Zhu XL, Ayala A, Zellweger R, et al. Peritoneal macrophages show increased cytokine gene expression following haemorrhagic shock. Immunology 1994;83:378-383.
20. Ertel W, Morrison MH, Ayala A, et al. Blockade of prostaglandin production increases cachectin synthesis and prevents depression of macrophage function after hemorrhagic shock. Ann Surg 1991;213: 265-271.
21. Cook JA, Geisel J, Tempel GE, et al. Endotoxin activation of eicanoid production by macrophages. In: Schlag G, Redl H, Eds. Pathophysiology of shock, sepsis, and organ failure. Berlin: Springer, 1993:518-527.
22. Zellweger R, Wichmann MW, Ayala A, et al. Females in proestrus state maintain splenic immune functions and tolerate sepsis better than males. Crit Care Med 1997;25:106-110.
23. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;229:1057-1061.
24. Angele MK, Ayala A, Monlfils BA, et al. Testosterone and/or low estradiol: Normally required but harmful immunologically for males after trauma-hemorrhage. J Trauma 1998;44:78-85.
25. Schröder J, Kahlke V, Fändrich F, et al. Glutamine dipeptide-supplemented parenteral nutrition reverses gut mucosal structure and interleukin-6 release of rat intestinal mononuclear cells after hemorrhagic shock. Shock 1998;10:26-31.
26. 2 receptor EP2 and EP4 are down-regulated in human mononuclear cells after injury. Surgery 2001; 130:249-255.
27. Breyer MD, Hao CM, Qi Z. Cyclooxygenase-2 selective inhibitors and the kidney. Curr Opin Crit Care 2001;7:393-400.
28. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959.